Your browser doesn't support javascript.
loading
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
Niederalt, Christoph; Kuepfer, Lars; Solodenko, Juri; Eissing, Thomas; Siegmund, Hans-Ulrich; Block, Michael; Willmann, Stefan; Lippert, Jörg.
Afiliación
  • Niederalt C; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany. christoph.niederalt@bayer.com.
  • Kuepfer L; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany.
  • Solodenko J; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany.
  • Eissing T; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany.
  • Siegmund HU; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany.
  • Block M; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 51368, Leverkusen, Germany.
  • Willmann S; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 42113, Wuppertal, Germany.
  • Lippert J; Clinical Pharmacometrics, Bayer AG Pharmaceuticals, 42113, Wuppertal, Germany.
J Pharmacokinet Pharmacodyn ; 45(2): 235-257, 2018 04.
Article en En | MEDLINE | ID: mdl-29234936
ABSTRACT
Proteins are an increasingly important class of drugs used as therapeutic as well as diagnostic agents. A generic physiologically based pharmacokinetic (PBPK) model was developed in order to represent at whole body level the fundamental mechanisms driving the distribution and clearance of large molecules like therapeutic proteins. The model was built as an extension of the PK-Sim model for small molecules incorporating (i) the two-pore formalism for drug extravasation from blood plasma to interstitial space, (ii) lymph flow, (iii) endosomal clearance and (iv) protection from endosomal clearance by neonatal Fc receptor (FcRn) mediated recycling as especially relevant for antibodies. For model development and evaluation, PK data was used for compounds with a wide range of solute radii. The model supports the integration of knowledge gained during all development phases of therapeutic proteins, enables translation from pre-clinical species to human and allows predictions of tissue concentration profiles which are of relevance for the analysis of on-target pharmacodynamic effects as well as off-target toxicity. The current implementation of the model replaces the generic protein PBPK model available in PK-Sim since version 4.2 and becomes part of the Open Systems Pharmacology Suite.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Distribución Tisular / Proteínas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Pharmacokinet Pharmacodyn Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Distribución Tisular / Proteínas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Pharmacokinet Pharmacodyn Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Alemania